Source: International Congress 2016 – Immunotherapy: the lethal weapon against thoracic malignancies?



Rating:

Share or cite this content

Citations should be made in the following way:
Sylvie Lantuejoul (Lyon, France). How to select good candidates for immunotherapy against thoracic malignancies. International Congress 2016 – Immunotherapy: the lethal weapon against thoracic malignancies?

Member's Comments

No comment yet.

Related content which might interest you: Rationale and targets of immunotherapy in thoracic malignancies Source: International Congress 2016 – Immunotherapy: the lethal weapon against thoracic malignancies? Year: 2016 Surgery following neoadjuvant therapy is safe and offers improved long-term prognosis Source: Annual Congress 2007 - Controversies in surgical oncology Year: 2007 Immunotherapy: a new standard of care in thoracic malignancies? Source: Eur Respir J, 51 (2) 1702072; 10.1183/13993003.02072-2017 Year: 2018 Current data on predictive markers for anti-angiogenic therapy in thoracic tumours Source: Eur Respir J 2010; 36: 915-924 Year: 2010 The clinical characteristics and treatment responses of tuberculosis in patients with malignancy on anti-cancer chemotherapy Source: Eur Respir J 2005; 26: Suppl. 49, 690s Year: 2005 Combination immunotherapy in mesothelioma: managing expectations and new toxicities Source: Virtual Congress 2021 – Lung cancer grand round Year: 2021 Indications for lung transplantation: from ideal recipients to challenging candidates Source: International Congress 2019 – Lung transplantation in 2019: where are we? Year: 2019 Which immunotherapy for which patients? Source: New biomarkers, molecules and therapeutic sequences for non small cell lung carcinoma in the era of precision medicine Year: 2019 Quality-of-life determinants in bronchogenic carcinoma patients candidates for curative surgery Source: Eur Respir J 2006; 28: Suppl. 50, 137s Year: 2006 Are biphosphonates efficient in the adjuvant treatment of lung cancer? Source: Eur Respir J 2006; 28: Suppl. 50, 754s Year: 2006 Cisplatin/vinorelbine remains a valid option for the front-line chemotherapy of NSCLC Source: Eur Respir J 2004; 24: Suppl. 48, 302s Year: 2004 Selection criteria in marginal lung cancer candidates Source: International Congress 2017 – ME8 Selection criteria in marginal lung cancer candidates Year: 2017 Can IASLC/ATS/ERS subtype help predict response to chemotherapy in small biopsies of advanced lung adenocarcinoma? Source: Eur Respir J 2014; 43: 1240-1242 Year: 2014 How to manage immune-related adverse effects in lung cancer patients under immunotherapy Source: CME Online 2019 Year: 2018 Prerequisites, potential and limits of thoracic surgery with curative intent for stage III NSCLC Source: International Congress 2019 – Locally advanced non-small cell lung cancer in 2019: novel diagnostic and therapeutic strategies to tackle complex stage III disease Year: 2019 Imaging in the evaluation of tumour response of thoracic malignancies Source: Annual Congress 2013 –PG2 Imaging in the management of thoracic malignancies Year: 2013